Article | February 28, 2019

How A Product NDC Change Could Impact Your Rare Disease Patient Base

Source: United BioSource LLC (UBC)

By Justin Gambill, Manager, Program Management

In the Rare Disease space, a product NDC may change for any of several reasons. Whether it’s a new product formulation on the market or a new company inheriting a previously established product, it’s imperative to think through the potential impact that a product NDC change may have on your established patient population. Here are a few things to consider that could reduce potential therapy gaps for patients when an NDC change is imminent.

Here are a few ways that utilizing a HUB with experienced clinical staff may be able to assist in helping to overcome/address authorization denials.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Clinical Leader